Research Topics
| S A HalperinSummaryAffiliation: Dalhousie University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adultsS A Halperin
Departments of Pediatrics, Clinical Trials Research Center, Dalhousie University and the IWK Grace Health Centre, 5850 University Avenue, Halifax, Canada
Vaccine 18:1312-9. 2000..We conclude that this adult formulation 5-component acellular pertussis vaccine is safe and immunogenic in adolescents and adults and is a candidate vaccine for adolescent and adult immunization programs...
Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trialScott A Halperin
Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, NS
CMAJ 169:111-7. 2003..We evaluated the effect of an oral dietary supplement derived from the edible microalga Chlorella pyrenoidosa on immune response after influenza vaccination...- A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvantScott A Halperin
Department of Pediatrics, Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 University Avenue, Halifax, NS, Canada B3J 3G9
Vaccine 21:2461-7. 2003.... - Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccineScott A Halperin
Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 University Avenue, 8 West Research, Halifax, NS, Canada B3J 3G9
Vaccine 21:2298-306. 2003..However, parents will still need to be aware of the high rates of injection site reactions expected after a fifth dose of acellular pertussis vaccine... - Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind studyScott A Halperin
Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, NS
Clin Invest Med 25:243-51. 2002..The objective of this study was to measure the safety and immunogenicity of a meningococcal C conjugate vaccine when given with routine childhood vaccines... - Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and childrenScott A Halperin
Department of Pediatrics, Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 University Avenue, NS, B3J 3G9, Halifax, Canada
Vaccine 20:1240-7. 2002..We conclude that the cell culture-derived vaccine was safe and immunogenic in children, healthy adults and seniors... - Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adultsS A Halperin
Department of Pediatrics, Dalhousie University and the IWK Grace Health Centre, Halifax, Nova Scotia, Canada
Pediatr Infect Dis J 19:276-83. 2000..Pertussis is increasingly recognized as an important cause of cough illness in adolescents and adults... - A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infectionS A Halperin
Department of Pediatrics, Dalhousie University and the IWK Grace Health Centre, Halifax, Nova Scotia, B3J 3G9 Canada E mail
Pediatrics 104:e42. 1999..Although epidemiologic investigations of outbreaks have suggested a benefit, there have been no prospective studies evaluating the efficacy of chemoprophylaxis in preventing secondary cases of pertussis... - Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of ageS A Halperin
Dalhousie University, Halifax, Canada
Pediatr Infect Dis J 18:772-9. 1999..This study compared a fifth dose of an acellular and a whole cell pertussis vaccine in 4- to 6-year-old children previously immunized with four doses of acellular or whole cell pertussis vaccine... - Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for S A Halperin
Dalhousie University and the IWK Grace Health Centre, Halifax, Nova Scotia, Canada
Clin Infect Dis 28:995-1001. 1999..influenzae type b polysaccharide after the primary three-dose series, mixing of the vaccines in a single syringe likely induced immunologic priming, as suggested by the high antibody levels after the booster dose... - Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT)S A Halperin
Department of Pediatrics, Dalhousie University, IWK Grace Health Centre, Halifax, Nova Scotia, Canada
Clin Infect Dis 28:1238-43. 1999..2% vs. 4.9%; P = .001) in infants under <6 months of age than in those > or =6 months. Pertussis continues to cause significant morbidity and occasional mortality in Canada, particularly in young infants... - Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussisJ B Knight
Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University and the IWK Health Centre, Halifax, NS, Canada
Clin Exp Immunol 144:543-51. 2006..pertussis in BALB/c mice. These data indicate that the type I domain of FHA is a protective antigen in mice and may serve as a candidate for inclusion in new acellular pertussis vaccines... - Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infectionsS A Halperin
Department of Pediatrics, Dalhousie University and the IWK Grace Health Centre, Halifax, Nova Scotia, Canada
Pediatrics 100:65-71. 1997..99% at the 5% level to detect a difference in failure rates of 10% and a power of 80% to detect a difference of 5%. We conclude that 7 days of erythromycin estolate is as effective as 14 days for the eradication of B pertussis... - Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordoniiS F Lee
Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University, Halifax, Nova Scotia, Canada B3H 3J5
Infect Immun 67:1511-6. 1999..In conclusion, a fragment of the S1 subunit of PT was successfully surface expressed in S. gordonii; the recombinant S1 fragment was found to be immunogenic and could induce protection against the toxic effect of PT in mice... - Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlersScott A Halperin
Clinical Trials Research Center, Dalhousie University and the IWK Health Centre, 5850 5980 University Avenue, Halifax, Nova Scotia, Canada B3K 6R8
Vaccine 24:4017-23. 2006..Recently, another DTaP-IPV-Hib (Infanrix-IPV-Hib) became available. Data on the interchangeability of these products was lacking... 
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of ageScott A Halperin
Clinical Trials Research Center, Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, Halifax, Nova Scotia, Canada
Vaccine 27:2540-7. 2009..All vaccine formulations were well tolerated. The three PRP-OMPC formulations met prespecified immunogenicity criteria, and the one with the lowest PRP-OMPC concentration was selected for further optimization of immunogenicity...- Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old childrenScott A Halperin
Clinical Trials Research Center, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
Hum Vaccin 1:245-50. 2005..8 microg/mL in PRP-T/HBV10 recipients and 9.4 microg/mL in PRP-OMPC/HBV15 recipients. We conclude that the hexavalent formulations appear generally well tolerated and immunogenic as a booster dose in these toddlers... - Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines inBeth A Halperin
Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, Nova Scotia, Canada
Pediatr Infect Dis J 21:399-405. 2002.... - Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACELScott A Halperin
Dalhousie University, Canadian Centre for Vaccinology, Departments of Pediatrics and Microbiology and Immunology, IWK Health Centre, 5850 5980 University Avenue, Halifax, Nova Scotia, B3K 6R8, Canada
Expert Opin Biol Ther 6:807-21. 2006..These products have been demonstrated to be safe, immunogenic and effective for the control of pertussis and the other included diseases... - Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum womenB A Halperin
Clinical Trials Research Center, Canadian Center for Vaccinology, Canada
Clin Infect Dis 53:885-92. 2011..We sought to determine whether the antibody response to tetanus-diphtheria-acellular pertussis vaccine (Tdap) is sufficiently rapid to support the cocoon strategy... - Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in miceP P Mallaley
Department of Microbiology and Immunology, Faculty of Medicine, Halifax, Canada
Can J Microbiol 52:436-44. 2006..mutans PM14 showed a decreased in B. pertussis lung colony count (P = 0.03) on day 3 compared with control mice colonized by the parent S. mutans 834... - Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlersS A Halperin
Clinical Trials Research Center, Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, 5850 5980 University Avenue, Halifax, NS, B3K 6R8, Canada
Eur J Clin Microbiol Infect Dis 29:259-67. 2010..Serogroup C titers were comparable following a single dose of MenACWY-CRM or MenC at 12 months. MenACWY-CRM is well tolerated and immunogenic given at 12 months, or two doses at 6 and 12 months of age... - An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine anJoanne M Langley
Department of Pediatrics, Dalhousie University, Halifax, NS, Canada
Vaccine 25:1121-5. 2007..Fever and injection site reactions are less common in 4-6 year-old-children who receive a dTap vaccine compared to DTaP-IPV, without inferior immunogenicity... - Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adultsShelly A McNeil
Clinical Trials Research Center, IWK Health Centre and QEII Health Sciences Centre, Dalhousie University, 5850 5980 University Avenue, Halifax, NS B3K 6R8, Canada
Vaccine 25:3464-74. 2007.... - Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adultsScott A Halperin
Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 5980 University Avenue, Halifax, NS, Canada B3K 6R8
Vaccine 24:20-6. 2006..Many individuals do not respond to a three-dose series of hepatitis B vaccine (HBV) and most do not achieve a protective antibody response until after dose 2 or 3... - Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordoniiM L Mayer
Canadian Center for Vaccinology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
Scand J Immunol 69:351-6. 2009..gordonii activates DC predominantly through a MyD88-dependent and TRIF-independent pathway. This activation can be attributed to multiple immunostimulatory components present within S. gordonii bacterial cells... - Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adultsScott A Halperin
Dalhousie University, Halifax, Nova Scotia, Canada
Hum Vaccin 1:37-42. 2005..We conclude that this trivalent, split virion, inactivated nasal influenza vaccine formulated with lipid/polysaccharide molecule carriers is well tolerated and modestly immunogenic in healthy adults... - How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?Scott A Halperin
Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
Pediatr Infect Dis J 25:195-200. 2006.... - Evaluation of a tuberculosis screening program at a children's hospitalS A Halperin
Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
Am J Infect Control 20:19-23. 1992.... - Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adultsScott A Halperin
Clinical Trials Research Center, Dalhousie University, The IWK Health Centre, Halifax, NS, Canada
Vaccine 25:450-7. 2007.... - Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of ageScott A Halperin
Clinical Trials Research Center, Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, 5850 5980 University Avenue, Halifax, Nova Scotia, Canada B3K 6R8
Vaccine 27:2701-6. 2009..In children primed with MMR and varicella vaccine, MMRV had non-inferior immunogenicity and similar safety profiles as a second dose of licensed MMR and varicella vaccine administered concomitantly... - Pertussis immunization in paediatric healthcare workers: knowledge, attitudes, beliefs, and behaviourKarina A Top
Department of Pediatrics, Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada
Vaccine 28:2169-73. 2010..There is a widespread acceptance of pertussis immunization among paediatric HCWs. Stated intentions may be poorly predictive of behaviour. Education and institutional or public funding may improve vaccine uptake... - Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine modelMarc Mansour
ImmunoVaccine Technologies Inc, Dalhousie University, Halifax, Nova Scotia, Canada
Clin Vaccine Immunol 14:1381-3. 2007.... - Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adultsJoanne M Langley
Division of Infectious Diseases, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada
Vaccine 24:1601-8. 2006..Further testing of this nasal influenza vaccine is warranted to determine its safety and immunogenicity in these populations and its efficacy in the prevention of clinical illness... - Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United StatesScott A Halperin
Dalhousie University, IWK Health Centre, Halifax, Nova Scotia B3K 6R8, Canada
Pediatr Infect Dis J 24:S141-6. 2005..In Canada, the epidemiology of pertussis has changed during the past decade such that more cases occur in adolescents than in any other age cohort... - A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trialJoanne M Langley
Clinical Trials Research Center, Dalhousie University and the IWK Health Centre, 5850 University Avenue, Halifax, Canada NS B3J 3G9
Vaccine 21:3863-6. 2003..These factors should be considered by vaccine researchers in the recruitment process of clinical trials... - Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in miceSong F Lee
Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University, Halifax, Nova Scotia, Canada B3H 3J5
FEMS Microbiol Lett 208:175-8. 2002..In conclusion, long-term oral colonization of BALB/c mice with our recombinant S. gordonii was established and the colonization elicited mucosal antibodies against PT and SpaP... - Expression of diphtheria toxin in Streptococcus mutans and induction of toxin-neutralizing antiseraC W Lee
Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University, Halifax, NS, Canada
Can J Microbiol 51:841-6. 2005..The potential of using S. gordonii as a live vaccine against diphtheria faces major challenges in the expression of DTX in this organism and in the induction of high-titer toxin-neutralizing antibodies... - The control of pertussis--2007 and beyondScott A Halperin
Department of Pediatrics, Dalhousie University, Halifax, NS, Canada
N Engl J Med 356:110-3. 2007 - Has the change to acellular pertussis vaccine improved or worsened pertussis control?Scott A Halperin
Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, Halifax, NS
CMAJ 175:1227. 2006 - Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteersShelly A McNeil
Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
Clin Infect Dis 41:1114-22. 2005..New molecular techniques have allowed the previous obstacles to be largely overcome... - Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric proteinSong F Lee
Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University, Halifax, Nova Scotia, Canada B3H 3J5
Infect Immun 71:2272-5. 2003..01) from that of the sham control group. Thus, a divalent S1 fragment CtxA2B chimera is an immunogenic antigen and can elicit a protective immunity... - Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)Alexander Doroshenko
Canadian Center for Vaccinology, Departments of Pediatrics, Dalhousie University and IWK Health Centre, Halifax, Nova Scotia, Canada
Expert Rev Vaccines 8:679-88. 2009.... - Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trialMatthew D Snape
Oxford Vaccine Group, University of Oxford, England
JAMA 299:173-84. 2008..However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed... - Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impactDanuta M Skowronski
University of British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
Pediatrics 112:e453. 2003.... - A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trialDavid W Scheifele
Canadian Association for Immunization Research and Evaluation CAIRE and the Vaccine Evaluation Center, BC Children s Hospital and the University of British Columbia, Vancouver, British Columbia, Canada
Pediatr Infect Dis J 24:1059-66. 2005..Large injection site reactions commonly follow booster doses of diphtheria-tetanus-acellular pertussis (DTaP) vaccines at 4-6 years of age. A vaccine with lower diphtheria and pertussis dosage (Tdap) might be better tolerated for this dose... - Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007David W Scheifele
Division of Pediatric Infectious and Immunologic Diseases, University of British Columbia, Vancouver, British Columbia
Pediatr Infect Dis J 27:755-7. 2008..Surveillance at 12 pediatric centers in 2004-2007 indicates that vaccine failures remain rare and case totals approach an irreducible minimum, with no age shift... - Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of ageDavid W Scheifele
Vaccine Evaluation Center, BC Children s Hospital, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
Vaccine 24:2057-64. 2006..008) and HB responses were reduced (p=0.006) with concurrent dosing, the latter possibly from same thigh injection with DTaP.IPV/Hib. We conclude that PCV7, DTaP.IPV/Hib and HB are compatible with concurrent, separate injections... - Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and reviewDanuta M Skowronski
British Columbia Centre for Disease Control, St Paul s Hospital and University of British Columbia, Vancouver, British Columbia V5Z 4R4, Canada
Clin Infect Dis 36:e1-4. 2003..Adult booster immunization against pertussis should be considered to protect adults themselves from this illness and its potential complications... - Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002Dorothy L Moore
Montreal Children s Hospital, McGill University Health Centre, Quebec, Canada
Pediatr Infect Dis J 23:568-71. 2004..Seven cases of encephalopathy began within 7 days after pertussis vaccination, but a more likely cause was found in each instance. No attributable case followed administration of >6.5 million doses of vaccine... - Pertussis--a disease and vaccine for all agesScott A Halperin
N Engl J Med 353:1615-7. 2005 - Pertussis control in CanadaScott A Halperin
CMAJ 168:1389-90. 2003 - Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccinePenelope H Dennehy
Division of Pediatric Infectious Diseases, Rhode Island Hospital and the Department of Pediatrics, Brown Medical School, Providence, 02903, USA
Pediatr Infect Dis J 24:481-8. 2005..Rotavirus is a major cause of gastroenteritis in children worldwide and is estimated to be responsible for more than 500,000 physician visits, 50,000 hospitalizations and 20 deaths in the United States each year... - Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the futureScott A Halperin
J Pediatr 149:589-91. 2006 - Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in CanadaRaymond S W Tsang
National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
J Clin Microbiol 42:5364-7. 2004..At least one of the novel mutations identified was found to involve a surface epitope that has been mapped by serum antibodies from infected or vaccinated subjects... - Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in CanadaLynda K Mikelova
J Pediatr 143:576-81. 2003..Leukocytosis and pneumonia are predictors of a poor outcome; however, rapid progression of the disease may make interventions difficult... - Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young childrenDavid W Scheifele
Vaccine Evaluation Center, BC Children s Hospital and the University of British Columbia, Vancouver, BC, Canada
Pediatr Infect Dis J 26:387-92. 2007.... - The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in CanadaJulie A Bettinger
Vaccine Evaluation Center, BC Children s Hospital and the University of British Columbia, Vancouver, British Columbia, Canada
Pediatr Infect Dis J 26:31-5. 2007..To assess effects on pertussis epidemiology of this nationwide change, we analyzed hospitalizations during 1991-2004 using the Canadian Immunization Monitoring Program, Active (IMPACT) pertussis database...